The International Vaccine Institute

We are a team of biomedical scientists, infectious disease experts, health professionals, and humanitarian leaders.We are dedicated to enabling the world’s most vulnerable people to live full, productive lives, by accelerating R&D for critical vaccines through:

  • Discovery optimization
  • Development networks
  • Reference labs and assays
  • Humanitarian swift teams

Spanning the spectrum from discovery through development, to delivery and capacity building

Discover

  • Design and formulate new vaccines, optimize production processes for industrial scale-up, and develop new technologies to support clinical testing of vaccines in humans.

Develop

  • Transfer technology to manufacturers and partner with them to develop and commercialize vaccines – including sponsoring and supporting clinical trials, registration, WHO prequalification – for the public-sector market.
  • Lead and manage private-public partnerships, and pool resources and funding from different sectors to develop vaccines.

Deliver

  • Accelerate vaccine introduction by generating data on the need for vaccines (numbers of deaths and illnesses, high-risk populations, economic costs of disease) for governments and policymakers .
  • Implement vaccine delivery and effectiveness studies to see how well vaccines work in real-life situations and to measure programmatic feasibility.
  • Conduct research on vaccine safety with focus on special populations like pregnant women, refugees and internally displaced people.

Build Capacity

  • Ensure vaccine security and self-reliance in developing countries through our technical assistance, tech transfer, training programs and annual Vaccinology Course.

OUR APPROACH

IVI develops and delivers vaccines against infectious diseases with limited commercial
potential yet high public health importance

VACCINE PIPELINE

Several vaccine candidates under development by IVI

  • Vaccines under different stages of development.
  • Bivalent inactivated oral cholera vaccine is first product licensed and approved by WHO.
  • Vi-DT typhoid conjugate vaccine is the next vaccine in the pipeline (year 2020).

  • Vaccines under different stages of development.
  • Bivalent inactivated oral cholera vaccine is first product licensed and approved by WHO.
  • Vi-DT typhoid conjugate vaccine is next vaccine out of pipeline (year 2020).

IVI’s programs combat infectious diseases that threaten global health

OverviewCurrent Work

Cholera

  • Accelerates development and delivery of oral cholera vaccines
  • 2 vaccines WHO-prequalified
  • Vaccination campaigns in Nepal, Ethiopia, Malawi and Mozambique

Typhoid

  • Accelerates development and delivery of oral cholera vaccines
  • Vi-DT conjugate vaccine currently in Phase 2 trial in the Philippines
  • Severe typhoid surveillance in Africa

Dengue

  • Increases dengue vaccine access for developing countries through policy and advocacy
  • Expanded scope to Zika, chikungunya and Aedes-transmitted infections by forming GDAC

MERS

  • Accelerates development of MERS vaccines for future outbreaks
  • Partnership with GeneOne to develop their DNA-based vaccine candidate
DONATE